Bristol-Myers Squibb is rolling up the Amylin tent in San Diego. After buying the smaller drugmaker last year, Bristol-Myers plans to shut down its former headquarters and lay off at least 400 workers.
Some Big Pharma heavyweights are duking it out for Brazil's Aché Laboratorios Farmaceuticos. Reuters sources say Pfizer, Novartis and Abbott Laboratories are in the fight, sizing up second-round bids in a deal worth around $5 billion.
Cardiac Science is parting ways with some of its mainstay technologies, selling its diagnostic cardiology unit to Mortara Instrument and doubling down on its automated external defibrillator business.
Apparently, investors were right about Obagi Medical Products. After Merz Pharma trumped Valeant Pharmaceuticals' offer for the skin-care company, the stock jumped more than 8%--significantly past Merz's $22-per-share bid. They were expecting a bidding war.
Elan has wrapped up its $3.25 billion deal to sell its stake in Tysabri to Biogen Idec and begun to pivot to the next chapter in its storied journey, ready to unleash a burst of new acquisitions after it hopes to bury a buyout offer from an unwelcome suitor.
Abbott Laboratories is largely focused on medical devices and diagnostics since spinning its innovative drugs business off into AbbVie, but Reuters reports the company is bidding on Brazilian drugmaker Aché Laboratorios Farmaceuticos, which could be worth up to $5 billion.
In another early-stage bet, AstraZeneca's MedImmune unit acquired the biotech AlphaCore Pharma. The deal comes as AstraZeneca reboots a floundering R&D effort and adds a recombinant LCAT enzyme therapy from AlphaCore that could combat cardiovascular disease.
Thermo Fisher Scientific has leapt into the lead in the bidding war for Life Technologies, Reuters ' sources say, stepping in with an offer that values the company at about $12 billion.
Over the summer, Biomet announced it was mulling a spin-out its 3i dental device unit, but now the company has scrapped those plans, at least for the moment.
Drugmakers are circling Optimer Pharmaceuticals, the antibiotics maker that says it's considering a sale. And that includes GlaxoSmithKline, Astellas Pharma, AstraZeneca and Cubist Pharmaceuticals, Bloomberg sources say, for a deal worth as much as $1 billion.